Rifamycin
Aemcolo (rifamycin) is a small molecule pharmaceutical. Rifamycin was first approved as Aemcolo on 2018-11-16. It is known to target solute carrier organic anion transporter family member 1A2, solute carrier organic anion transporter family member 2B1, solute carrier organic anion transporter family member 1B1, and solute carrier organic anion transporter family member 1B3.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Aemcolo
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Rifamycin sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| AEMCOLO | RedHill Biopharma | N-210910 RX | 2018-11-16 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| aemcolo | New Drug Application | 2023-12-15 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
RIFAMYCIN SODIUM, AEMCOLO, REDHILL | |||
| 2028-11-16 | GAIN | ||
| 2023-11-16 | NCE | ||
ATC Codes
A: Alimentary tract and metabolism drugs
— A07: Antidiarrheals, intestinal antiinflammatory/antiinfective agents
— A07A: Intestinal antiinfectives
— A07AA: Antibiotics, intestinal
— A07AA13: Rifamycin
D: Dermatologicals
— D06: Antibiotics and chemotherapeutics for dermatological use
— D06A: Antibiotics for topical use
— D06AX: Other antibiotics for topical use in atc
— D06AX15: Rifamycin
J: Antiinfectives for systemic use
— J04: Antimycobacterials
— J04A: Drugs for treatment of tuberculosis
— J04AB: Antibiotics, antitubercular
— J04AB03: Rifamycin
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01A: Antiinfective ophthalmologics
— S01AA: Antibiotics, ophthalmologic
— S01AA16: Rifamycin
— S02: Otologicals
— S02A: Antiinfective drugs, otologic
— S02AA: Antiinfectives
— S02AA12: Rifamycin
HCPCS
No data
Clinical
Clinical Trials
31 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 3 | 4 | 4 | 3 | — | 11 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 2 | 1 | 2 | 1 | 1 | 6 |
| Latent tuberculosis | D055985 | — | Z22.7 | 2 | 1 | 1 | 2 | — | 5 |
| Infections | D007239 | EFO_0000544 | — | — | 1 | — | 1 | — | 2 |
| Impacted tooth | D014095 | HP_0011079 | K01.1 | — | — | — | 1 | — | 1 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.9 | — | — | — | 1 | — | 1 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | 1 | — | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diarrhea | D003967 | HP_0002014 | R19.7 | — | 4 | 2 | — | — | 6 |
| Dysentery | D004403 | EFO_1001869 | — | — | 3 | 2 | — | — | 5 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 1 | 1 | 2 | — | — | 3 |
| Hiv | D006678 | — | — | 1 | — | 1 | — | — | 2 |
| Syndrome | D013577 | — | — | — | 2 | 1 | — | — | 2 |
| Pulmonary tuberculosis | D014397 | EFO_1000049 | A15 | — | 1 | 1 | — | — | 2 |
| Immune reconstitution inflammatory syndrome | D054019 | — | — | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diverticulitis | D004238 | EFO_1001460 | K57 | — | 1 | — | — | 1 | 2 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | 1 | 2 | — | — | — | 2 |
| Gastrointestinal diseases | D005767 | — | — | — | 1 | — | — | — | 1 |
| Digestive system diseases | D004066 | HP_0011024 | K92.9 | — | 1 | — | — | — | 1 |
| Gastroenteritis | D005759 | EFO_1001463 | K52.9 | — | 1 | — | — | — | 1 |
| Brain diseases | D001927 | HP_0001298 | G93.40 | — | 1 | — | — | — | 1 |
| Hepatic encephalopathy | D006501 | — | K72.91 | — | 1 | — | — | — | 1 |
| Communicable diseases | D003141 | — | — | — | 1 | — | — | — | 1 |
| Irritable bowel syndrome | D043183 | EFO_0000555 | K58 | — | 1 | — | — | — | 1 |
| Hyperammonemia | D022124 | HP_0001987 | E72.20 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 3 | — | — | — | — | 3 |
| Drug interactions | D004347 | — | — | 2 | — | — | — | — | 2 |
| Herb-drug interactions | D041743 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Conjunctivitis | D003231 | HP_0000509 | H10 | — | — | — | — | 1 | 1 |
| Ophthalmia neonatorum | D009878 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Rifamycin |
| INN | rifamide |
| Description | Rifamycin SV is a member of the class of rifamycins that exhibits antibiotic and antitubercular properties. It has a role as a bacterial metabolite, an antimicrobial agent and an antitubercular agent. It is a member of rifamycins, an acetate ester, a cyclic ketal, a lactam, a macrocycle, a polyphenol and an organic heterotetracyclic compound. It is a conjugate acid of a rifamycin SV(1-). |
| Classification | Small molecule |
| Drug class | antibiotics (Streptomyces strain); antibiotics (rifamycin derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(cc(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C |
Identifiers
| PDB | — |
| CAS-ID | 6998-60-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL437765 |
| ChEBI ID | 29673 |
| PubChem CID | 6324616 |
| DrugBank | DB11753 |
| UNII ID | TS121H7U7E (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
SLCO1A2
SLCO1A2
SLCO2B1
SLCO2B1
SLCO1B1
SLCO1B1
SLCO1B3
SLCO1B3
Organism
Homo sapiens
Gene name
SLCO1A2
Gene synonyms
OATP, OATP1, OATP1A2, SLC21A3
NCBI Gene ID
Protein name
solute carrier organic anion transporter family member 1A2
Protein synonyms
OATP-1, OATP-A, organic anion transporting polypeptide A, Organic anion-transporting polypeptide 1, Sodium-independent organic anion transporter, solute carrier family 21 (organic anion transporter), member 3, Solute carrier family 21 member 3
Uniprot ID
Mouse ortholog
—
—
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 13,707 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
208 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use